Huihe introduces strategic investor Toujing Life to accelerate the clinical development of the first self-developed pipeline CC312

Recently, Huihe Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Huihe Biotechnology") completed an A++round of financing, exclusively invested by strategic investor Shanghai Toujing Life Technology Co., Ltd. (hereinafter referred to as "Toujing Life"). Toujing Life's exclusive investment in Huihe Biotechnology is optimistic about the company's independently developed and globally leading new generation co stimulatory signal triple antibody TCE innovative drug platform (TriTE) ™） The unique advantages in the treatment of tumors and autoimmune diseases, as well as the differentiated clinical value and commercialization potential of the first research pipeline (CC312) in various B-cell abnormality related autoimmune diseases such as systemic lupus erythematosus (SLE); The company's development direction is also highly aligned with the long-term strategy of Touareg Life, which aims to extend its diagnostic technology advantages to the treatment field and build a full life cycle service capability for life and health. Yuanyi Capital serves as the financial advisor for this round of financing for Huihe Biotechnology.